MoonLake Immunotherapeutics reported net income of -$61.80M for the quarter ended Jun 2026. This income statement covers 23 quarters of results from Dec 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating items | |||||||||||||||||||||||
| Research & DevelopmentR&D | 0.67M | 35.53M | 10.45M | 11.40M | 9.02M | 11.37M | 7.42M | 8.70M | 7.59M | 8.10M | 13.01M | 23.66M | 35.74M | 40.36M | 36.46M | 49.76M | 60.63M | 56.01M | 54.52M | 50.22M | |||
| Selling, General & AdministrativeSG&A | 5.60M | 18.05M | 5.49M | 6.25M | 5.75M | 5.33M | 5.52M | 4.48M | 5.39M | 6.93M | 6.81M | 6.92M | 7.38M | 9.22M | 11.03M | 10.94M | 10.80M | 9.21M | 15.51M | 11.44M | |||
| Operating ExpensesOpex | 6.27M | 53.58M | 15.94M | 17.65M | 14.77M | 16.70M | 12.93M | 13.19M | 12.98M | 15.03M | 19.82M | 30.58M | 43.11M | 49.58M | 47.48M | 60.70M | 71.43M | 65.22M | 70.02M | 61.66M | |||
| Operating IncomeOp. Inc | -6.27M | -53.58M | -15.94M | -17.65M | -14.77M | -16.70M | -12.93M | -13.19M | -12.98M | -15.03M | -19.82M | -30.58M | -43.11M | -49.58M | -47.48M | -60.70M | -71.43M | -65.22M | -70.02M | -61.66M | |||
| EBIT | -6.27M | -53.58M | -15.94M | -17.65M | -14.77M | -16.70M | -12.93M | -13.19M | -12.98M | -15.03M | -19.82M | -30.58M | -43.11M | -49.58M | -47.48M | -60.70M | -71.43M | -65.22M | -70.02M | -61.66M | |||
| Non-operating items | |||||||||||||||||||||||
| Non Operating Interest Expenses | 657.00 | 0.02M | 2.04M | 3.20M | 1.99M | 2.27M | 2.63M | ||||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 0.00M | 0.00M | 0.01M | ||||||||||||||||||||
| Other Non Operating IncomeOther Non Op Inc. | -0.02M | -0.17M | 0.27M | 0.25M | 0.09M | 0.13M | 0.72M | 0.84M | 1.39M | 7.19M | 5.92M | 5.90M | 7.09M | 3.23M | 7.10M | 6.78M | 4.05M | 4.44M | 3.21M | 2.58M | |||
| Non Operating IncomeNon Op. Inc. | 0.00M | 0.00M | 0.01M | ||||||||||||||||||||
| Net income details | |||||||||||||||||||||||
| EBT | -6.29M | -53.64M | -15.87M | -17.41M | -14.73M | -16.46M | -12.21M | -12.34M | -11.59M | -7.84M | -13.90M | -24.68M | -36.02M | -46.35M | -40.41M | -55.96M | -70.58M | -62.77M | -69.08M | -61.72M | |||
| Tax ProvisionsTaxes | 0.00M | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M | 0.03M | 0.04M | 0.07M | 0.08M | 0.09M | 0.04M | 0.15M | 0.10M | 0.12M | 0.25M | 0.62M | 0.09M | ||||
| Profit After TaxPAT | -6.29M | -53.81M | -15.88M | -17.42M | -14.74M | -16.47M | -12.22M | -12.35M | -11.62M | -7.89M | -13.97M | -24.76M | -36.55M | -46.40M | -40.56M | -57.95M | -70.94M | -62.70M | -69.99M | -61.80M | |||
| Income from Non-Controlling InterestsInc. Minority | -5.30M | -4.63M | 0.64M | -3.22M | -2.30M | -2.19M | -0.45M | -0.30M | -0.49M | -0.73M | -0.79M | -0.66M | -0.86M | -0.97M | -0.59M | ||||||||
| Income from Continuing OperationsIncome (Continuing) | -6.29M | -53.64M | -15.88M | -17.42M | -14.74M | -16.47M | -12.22M | -12.35M | -11.62M | -7.89M | -13.97M | -24.76M | -36.11M | -46.40M | -40.56M | -56.05M | -70.69M | -63.02M | -69.71M | -61.80M | |||
| Consolidated Net IncomeConsol Net Inc. | -6.29M | -53.64M | -15.88M | -17.42M | -14.74M | -16.47M | -12.22M | -12.35M | -11.62M | -7.89M | -13.97M | -24.76M | -36.11M | -46.40M | -40.56M | -56.05M | -70.69M | -63.02M | -69.71M | -61.80M | |||
| Income towards Parent CompanyParent Net Inc | -6.29M | -53.64M | -15.88M | -17.42M | -14.74M | -16.47M | -12.22M | -12.35M | -11.62M | -7.89M | -13.97M | -24.76M | -36.11M | -46.40M | -40.56M | -56.05M | -70.69M | -63.02M | -69.71M | -61.80M | |||
| Net Income towards Common StockholdersNet Income | -6.29M | -53.64M | -15.88M | -17.42M | -14.74M | -16.47M | -12.22M | -12.35M | -11.62M | -7.89M | -13.97M | -24.76M | -36.11M | -46.40M | -40.56M | -56.05M | -70.69M | -63.02M | -69.71M | -61.80M | |||
| Additional items | |||||||||||||||||||||||
| EPS (Basic) | -0.42 | -3.62 | -3.17 | -0.49 | -0.40 | -0.56 | -0.31 | -0.28 | -0.22 | -0.16 | -0.22 | -0.39 | -0.57 | -0.74 | -0.64 | -0.89 | -1.12 | -0.98 | -0.98 | -0.84 | |||
| EPS (Diluted) | -0.65 | -0.15 | -1.08 | -0.49 | -0.40 | -0.56 | -0.31 | -0.28 | -0.22 | -0.16 | -0.22 | -0.39 | -0.57 | -0.74 | -0.64 | -0.89 | -1.12 | -0.98 | -0.98 | -0.84 | |||
| Shares Outstanding | 14.80M | 14.80M | 5.01M | 35.20M | 36.93M | 29.36M | 39.06M | 43.72M | 53.52M | 49.12M | 62.64M | 62.87M | 62.90M | 62.87M | 63.23M | 63.28M | 63.37M | 64.46M | 71.27M | 73.92M | |||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 9.69M | 360.00M | 14.75M | 35.20M | 36.93M | 29.36M | 39.06M | 43.72M | 53.52M | 49.12M | 62.64M | 62.87M | 62.90M | 62.87M | 63.23M | 63.28M | 63.37M | 64.46M | 71.27M | 73.92M | |||
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 12.13M | 12.16M | 11.74M | 52.70M | 52.70M | 52.70M | 52.70M | 62.45M | 53.56M | 62.97M | 62.87M | 62.87M | 63.05M | 63.08M | 63.47M | 63.47M | 63.70M | 71.37M | 73.62M | 85.11M | |||
| EBITDA | -6.27M | -53.58M | -15.94M | -17.65M | -14.77M | -16.70M | -12.93M | -13.19M | -12.98M | -15.03M | -19.82M | -30.58M | -43.11M | -49.58M | -47.48M | -60.70M | -71.43M | -65.22M | -70.02M | -61.66M | |||
| Interest ExpensesInt Expense | 657.00 | 0.02M | 2.04M | 3.20M | 1.99M | 2.27M | 2.63M | ||||||||||||||||
| Tax Rate | -0.01% | -0.05% | -0.05% | -0.06% | -0.07% | -0.09% | -0.08% | -0.25% | -0.56% | -0.50% | -0.32% | -0.26% | -0.09% | -0.38% | -0.17% | -0.16% | -0.40% | -0.90% | -0.15% |